Background: Alzheimer pathogenesis has been associated with a network of processes working
Introduction
protein (APP) processing [3] , protecting neurons from the peptide toxicity. Therefore, the amyloidogenic and cholinergic pathways, while being considered independent for years, share a number of molecular features that merge at several points. This intertwined correlation is part of a complex network of A-centred pathogenic events that may possibly account for the failure hitherto encountered with purely anti-amyloid strategies.
Figure 1. Rational Design of 1-5.
In this scenario, we envisaged the development of multitarget compounds, i.e. small molecules able to simultaneously address multiple targets critically involved in the AD network [11] [12] [13] , as a promising therapeutic choice. In particular, we sought to exploit the abovementioned mutual interactions between Aβ and cholinergic transmission by endowing singular chemical entities of both antiaggregating ability and cholinergic properties (i.e. AChE inhibition and nAChR activation). To this end, we followed a ligand-based approach and combined synergistic pharmacophores into chimera compounds 1-5 by linking a 1-(2-methoxybenzyl)-piperazine function to a carbazole moiety through different length spacers. Substituted carbazoles have shown to exert anti-amyloidogenic activity [14] , and to interact with the AChE gorge ( Figure 1 ) [15] . The selection of the 1-(2-methoxybenzyl)-piperazine function was based on the structural similarity between the ethyl-(2-methoxybenzyl)-amine group, that was already proven effective in recognizing the AChE catalytic site [16, 17] , and the 1-(2,4-dimethoxyphenyl)-piperazine moiety, which demonstrated leading properties for 7 nAChR activation [18] .
Materials & methods
Chemistry. Melting points were taken in glass capillary tubes on Buchi SMP-20 apparatus and are uncorrected. IR, electron impact (EI) mass, and direct infusion ESI-MS spectra were recorded on PerkinElmer 297, VG 7070E, and Waters ZQ 4000 apparatus, respectively. 
Synthesis of 4-(7-Bromoeptyloxy)-9H-carbazole (11
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Biology
Inhibition of AChE and BChE. The capacity of compounds 1-5 to inhibit human AChE and BChE activity was assessed using the Ellman's assay [19] . A Jasco V-530 double beam spectrophotometer connected to HAAKE DC30 thermostating system (Thermo Haake, Germany) was used. Binding to nicotinic receptor subtypes. Frozen cortex and hippocampus specimens taken from adult male Sprague-Dawley rats (Charles River, Calco Italy) were homogenised using a Potter homogenizer in an excess of buffer A (50 mM Tris-HCl, pH 7, 120 mM NaCl, 5 mM KCl, 1 mM MgCl2 and 2.5 mM CaCl2 and 2 mM phenylmethylsulfonyl fluoride), centrifuged (60 min at 30,000 x g), and rinsed twice. The homogenates were resuspended in the same buffer containing 20 g/ml of the protease inhibitors leupeptin, bestatin, pepstatin A, and aprotinin. The LIGAND program was used to calculate Ki values of all the tested compounds using data obtained from at least three independent saturation and competition binding experiments.
Agonism of nAChRs.
To test for agonism of α4β2 or α7 receptors, cRNAs encoding the receptor subunits were injected into defolliculated Xenopus oocytes. 50 nL of cRNA solution containing 100 ng/μL each of α4 and β2 or α7 was injected into each oocyte and they were incubated for three days at 18 °C for protein expression to take place. The oocytes were then subjected to two-electrode voltage clamp using an Axoclamp 2B (Axon Instruments, USA). Glass microelectrodes had a resistance of 0.5-1 MΩ when filled with 3 M KCl. The oocytes were clamped at -80 mV then ACh and compounds 1-5 were applied to the oocyte using an 8-channel perfusion system (Automate, USA). Currents were transferred to a PC and measured using Strathclyde Electrophysiology Software WinEDRv3.6.9. (Dr John Dempster, University of Strathclyde, UK). Currents in response to 1-5 were normalized to the response to ACh at the same concentration and in the same cell and plotted as % of ACh response ± SEM using Graphpad Prism 7.01.
Computational Methods
The docking simulations were performed using ICM 3.8 (Molsoft LLC, San Diego -CA, USA). The enzyme model was prepared starting from the crystallographic coordinates of the complex formed by human AChE with fasciculin (PDBid: 1B41) [24] according to procedure reported in Belluti et al. [25] . Hydrogen atoms were added. Polar hydrogen atoms and the positions of asparagine and glutamine side chain amidic groups were optimized and assigned the lowest energy conformation. After optimization, histidines were assigned the tautomerization state which improved the hydrogen bonding pattern. Fasciculin was deleted and only the enzyme chain was retained. Ligands were built defining the right bond orders, stereochemistry, hydrogen atoms, and protonation states. Each ligand was assigned the MMFF force field atom types and charges [26] .
The residues defining the binding pocket were selected according to the crystallographic poses of propidium in complex with the murine AChE (PDB code 1N5R) [27] and Donepezil (in complex with T. californica AChE, PDB code 1EVE) [28] . Sampling was performed using the Biased Probability Monte Carlo (BPMC) stochastic optimizer in an internal coordinate space as implemented in ICM [29] . Pre-calculated potential grid maps, representing Van der Waals potentials for hydrogens and heavier atoms, electrostatics, hydrophobicity, and hydrogen bonding, described the binding site. The adopted force field was a modified version of ECEPP/3 [30] . Based on the number of rotatable bonds in the ligand, the total number of BPMC steps to be carried out was calculated by an adaptive algorithm (thoroughness 1.0). The binding energy was assessed by means of the standard ICM empirical scoring function [31] .
Results & discussion
Compounds 1-5 were prepared following the synthetic procedures outlined in Figure 2 . Nucleophilic substitution of the commercially available 6 with the opportune dibromo alkane gave intermediates 7-11 according to the procedure reported in Rosini et al. [15] . 1-(2-methoxybenzyl)-piperazine (12), synthesized treating 1-cloromethyl-2-methoxybenzene with a large excess of piperazine, was then condensed with intermediates 7-11 under basic conditions to afford final compounds 1-5. Initially, to determine the potential interest of compounds 1-5 as multifunctional agents for AD treatment, their AChE inhibitory activity was evaluated on human recombinant AChE by the method of Ellman and coworkers [19] . The inhibitory activity towards BChE from human serum of 1-5 was also determined by the same assay. Values are the mean of two independent experiments, each performed in duplicate; c from reference [15] ; d from reference [32] ; nd stands for not determined.
As reported in Table 1 , AChE inhibition was strictly dependent on the chain length separating the pharmacophoric functions. The most effective compounds were 4 (IC50 = 0.773 M) and, albeit to a lower extent, 3 (IC50 = 2.39 M), having a six and five methylene spacer, respectively, between the carbazole unit and the benzyl-piperazine moiety. Notably, inhibition of ACh cleavage by 3 was in line with that of current anticholinesterase drugs galantamine and rivastigmine (Table 1) , while 4 performed slightly better.
Conversely, shortening (1 and 2) or lengthening (5) the flexible tether resulted in an evident drop in activity.
This behavior is typically related to a dual binding mode of inhibition [33] [34] [35] [36] , where a suitable chain length is determinant to allow compounds contacting the two recognition sites which distinguish the peculiar topology of AChE, namely internal and peripheral anionic sites [37] .
To verify this hypothesis and devise a structural explanation on how the length of the flexible linker modulates the AChE inhibitory potency of the synthesized compounds, docking simulations were performed at the human AChE (hAChE) gorge by means of ICM3.8 (Molsoft LLC, San Diego, CA-USA) for 4 and its homologues 3 and 5. Donepezil ( Figure 3A ) and the inhibitor of the peripheral anionic site (PAS) propidium were used for comparison ( Figure 3B ).
The model of the enzyme was based on the crystal structure of hAChE in complex with fasciculin (PDB code 1B41). The 4 hexyloxy spacer allows an optimal dual site interaction at both at the catalytic and at the PAS sites: a) the terminal benzyl group of the inhibitor establishes π -π interactions with Trp86; b) the protonated nitrogen atom can form a π -cation interaction with the side chain of Tyr337; and c) the carbazole group establishes π -π interactions with Trp286. Interestingly, when the predicted bound conformation of 4 is compared to the known pose of donepezil (Figure 2A ) it can be seen that it overlaps well (PBD code 1EVE). Moreover, the carbazole nitrogen of 4 perfectly overlaps with the phenantridinic nitrogen of the propidium bound conformation ( Figure 2B ). Derivatives with shorter (3) and longer (5) linkers cannot be efficiently fitted in the binding pocket ( Figure S1 and Figure S2 in Supporting Information).
Concerning the inhibition of human BChE (hBChE), the length of the spacer did not significantly influence the inhibitory profile, as all the compounds presented similar inhibitory values in the micromolar range (Table 1) . Interestingly, this resulted in a balanced dual AChE/BChE inhibitory potency for 3 and 4.With better understanding of the inter-relationship of AChE and BChE in the AD brain, this balanced action may have potential therapeutic benefits, as both enzymes are recognized therapeutic targets at different stages of the pathology. Indeed, as AD evolves, the activity of AChE decreases while that of BChE increases [5] , in an attempt to modulate ACh levels in cholinergic neurons. Therefore, the synergistic inhibition of both cholinesterase (ChE) enzymes might be a more valuable approach for the moderate form of the AD. As a part of our multitarget project, we sought to verify if anti-ChE activity of compounds 1-5 could be accompanied by effective nAChR activation, as we envisioned the weak perturbation of different AChmediated targets as a valuable strategy to gain potential additive or synergistic enhancement of cholinergic neurotransmission. Therefore, preliminary binding assays were carried out to assess whether compounds 1-5 could displace inhibition [38] .
To substantiate the mode of action toward nAChRs, we also tested synthesised compounds on α4β2 and α7 nAChRs subtypes, heterologously expressed in Xenopus oocytes by using two-electrode voltage clamp.
Membrane potential was clamped at -80 mV and, to evaluate the activity of compounds 1-5, they were applied at two different concentrations (10 and 100 µM) in comparison with the agonist ACh. While a negligible effect was detected at 10 μM concentration (see Table S1 in Supporting Information), a weak activation on membrane current for the α4β2 receptor subtype was observed at 100 µM for all compounds, ranging from 15 to 22% of the response to 100 μM ACh (Figure 4) . Conversely, no responses could be detected on α7 nAChR, probably because this receptor subtype has a lower sensitivity to ACh [39] or because of the fast desensitization which could considerably complicate the ion current measurements.
Low levels of persistent activation of α4β2 receptors may be beneficial in terms of improving the excitability of postsynaptic neurons or enhancing neurotransmitter release presynaptically.
Finally, to disclose the proposed dual interventions on cholinergic and amyloidogenic pathways, the ability of compounds 1-5 towards the inhibition of Aβ(1-42) self-aggregation was investigated. The carbazole building block (6) was also included in the study to clarify the role of this fragment. A ThT-based fluorimetric assay was used to quantify Aβ fibril formation in the presence and absence of inhibitor (Aβ/inhibitor ratio 5/1). Data in Table 1 show that all compounds at 10 µM concentration inhibited Aβ self-aggregation, with inhibition by 2-5 ranging from 28 to 36%, similarly to the known anti-aggregating compound curcumin (34.4±1.1%, at 10 µM) [40] . The observed efficacies are significantly higher with respect to the carbazole moiety alone, corroborating the importance of substitution for boosting the inhibitory capability towards A assembly.
Interestingly, any of the marketed AChEIs, including galantamine, display significant high antiaggregating ability (Table 1) . Consequently, these new compounds propose an expanded multitarget profile for AChEIs, through the incorporation of additional and mutual interconnected anti-AD properties.
Conclusion
The multifactorial nature of AD is a critical issue which hampers the discovery of effective disease modifying therapies. In this light, multitarget compounds have recently been proposed to address simultaneously multiple targets critically involved in the AD network [41] . By exploiting this approach, the present study provided compounds 3 and 4 which presented a moderate-affinity profile against all the selected targets. Particularly, a low but significant activation of α4β2 nAChRs (15-20% at 100 µM) was combined to a micromolar AChE inhibitory profile. This latter activity is not dissimilar to that of some of the current marketed drugs. What's more, the ability to reduce Aβ self-aggregation shown by 3 and 4 at 10 µM makes them very interesting starting points for further development. In fact, when two or more targets are interconnected, as for cholinergic neurotransmission (AChE, nAChRs) and amyloid, a weak perturbation of one or both partner systems might be sufficient to accomplish a significant modification of the whole scenario, in a synergistic way. Furthermore, the mild but multiple perturbation might prevent unwanted compensatory mechanisms that are typical of high-affinity single target compounds [42] .
Future perspectives
Despite the opportunities conceptually offered by the multitarget drug-design strategy and the enthusiasm generated around it, the effective development of multitarget drugs is extremely challenging. Indeed, the generation of a valuable multitarget drug is a compromise and balance iterative process.
From the start, selection of the targets is fundamental to establish whether their modulation could lead to additive effects or synergistic potentiation [43] . Herein, we envisaged the simultaneous modulation of human ChE and nAChRs as a suitable tool to synergistically turn up the cholinergic transmission, which is impaired in AD. More interestingly, based on the widely recognized cross-talk between nAChRs and the Aβ pathway, we proposed nAChR activation as a crucial tether between the symptomatic relief of cholinergic potentiation and the neuroprotective prospects of antiaggregating agents. Thus, by intervening on the three pathways, we aim to synergistically interfere with crucial points of recognized AD pathogenic players. Aware of the work still to be done in terms of potency, affinity-balancing and developing α7 agonism, we believe that these new compounds may represent a starting point for a further optimization process. We are also confident that our rationale may offer a valuable input towards translating the findings of network medicine into clinically actionable tools.
Executive summary
 AD has a multifactorial nature, with a network of simultaneous and synergistic processes.
 The rational design of single chemical entities addressing multiple targets is a promising and challenging strategy, with higher beneficial impact to confront AD.
 Selection of the targets is crucial to achieve additive effects or synergistic potentiation.
 The amyloidogenic and cholinergic pathways, while being considered independent for years, share a number of molecular features that merge at several points.
 The present study provides new molecules able to potentiate the cholinergic neurotransmission, by combining direct nicotinic receptor activation to acetylcholinesterase inhibition, and to inhibit Aβ aggregation.
 The obtained results offer a valuable input for a further optimization process.
